Atlas Trials

Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration

Clinical trial NCT05904691 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05904691
Sponsor
Ocugenix Corporation
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Neovascular Age-related Macular Degeneration (nAMD)
Start date
2023-11-01
Primary completion
2026-11-30
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.